Salud financiera de hoja de balance de Biomea Fusion

Salud financiera controles de criterios 4/6

Biomea Fusion tiene un patrimonio de los accionistas total de $18.7M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $46.4M y $27.7M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$44.69m
Patrimonio	US$18.72m
Total pasivo	US$27.67m
Activos totales	US$46.39m

Actualizaciones recientes sobre salud financiera

Artículo de análisis • Aug 17

Recent updates

Seeking Alpha • Oct 07

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Summary Biomea Fusion shares spiked on positive 52-week Phase II data for icovamenib in type 2 diabetes, then fell after a $25M fundraising announcement. BMEA's icovamenib showed durable HbA1c reductions in severe insulin-deficient and GLP-1 non-responder subgroups, but broader efficacy remains unproven in larger populations. Despite a strengthened cash position extending into late 2026, significant risks persist, including funding needs for further trials and competition from established GLP-1 therapies. Given the high risk, uncertain broad efficacy, and dilution, I remain on the sidelines, though BMEA could appeal to speculative investors seeking potential outsized returns. Read the full article on Seeking Alpha

Artículo de análisis • Aug 17

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Artículo de análisis • Sep 30

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Artículo de análisis • Jun 10

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Artículo de análisis • Feb 22

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Artículo de análisis • Nov 07

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Artículo de análisis • Jul 12

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Artículo de análisis • Mar 29

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($46.3M) de BMEA superan a sus pasivos a corto plazo ($9.3M).

Pasivo a largo plazo: Los activos a corto plazo de BMEA ($46.3M) superan a sus pasivos a largo plazo ($18.4M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: BMEA está libre de deudas.

Reducción de la deuda: BMEA no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 0.06%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: BMEA tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: BMEA tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 24.2% cada año

Descubre empresas con salud financiera

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/05/22 07:52
Precio de las acciones al final del día	2026/05/22 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Biomea Fusion, Inc. está cubierta por 15 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Naureen Quibria	Capital One Securities, Inc.
Yigal Nochomovitz	Citigroup Inc
Jonathan Wolleben	Citizens JMP Securities, LLC

Salud financiera de hoja de balance de Biomea Fusion

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Recent updates

Price target decreased by 9.7% to US$6.83

New minor risk - Market cap size

Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion, Inc., Annual General Meeting, Jun 10, 2026

Biomea Fusion, Inc. Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

New major risk - Financial position

Biomea Fusion Presents Phase II Covalent-111 Data In Type 2 Diabetes At 19th International Conference On Advanced Technologies And Treatments For Diabetes

Biomea Fusion, Inc. Presents Covid-111 Study Results At the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Co-Founder recently bought US$55k worth of stock

Biomea Fusion, Inc. Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide At Obesityweek®? 2025

Price target decreased by 10% to US$7.17

Biomea Fusion, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2025

Biomea Fusion, Inc. Announces First Patient Dosed in Phase I Study of BMF-650 A Next-Generation Oral GLP-1 Receptor Agonist

Biomea Fusion Announces Positive 52-Week Results from Phase II Covid-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion, Inc. Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Price target decreased by 27% to US$8.29

Biomea Fusion, Inc. Announces Board Changes

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Index

Biomea Fusion, Inc. Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

New major risk - Shareholder dilution

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent Flt3 Inhibitor Bf-500 in Relapsed or Refractory Acute Leukemia At Eha 2025

New major risk - Share price stability

Price target decreased by 14% to US$20.00

Biomea Fusion, Inc. Selects for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Price target decreased by 13% to US$20.50

Biomea Fusion, Inc., Annual General Meeting, Jun 11, 2025

Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt

Biomea Fusion, Inc. Announces Chief Executive Officer Changes

Biomea Fusion Inc. Announces Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Price target decreased by 34% to US$28.11

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion, Inc. Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023